It's the reference to regulatory consultants that interests me. It seems that would be a request from FDA for a bit more info OR a change of process/timing that the consultants can provide advice on. If it's the latter, then I hope it's a positive sign. Paul's upbeat commentary on moiety in the virtual presentation makes me think that FDA is all over this stuff and might be prepared to move it a bit quicker. Of course this is driven by optimism on my part - its time i had a win from a Trading Halt (as every other one for my other shares has been bad ness or CR).
PAR Price at posting:
$1.69 Sentiment: Buy Disclosure: Held
